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Introduction: Peste des petits ruminants (PPR) is a OIE-listed disease of sheep and goats, 
caused by PPRV, a Morbillivirus, from the Paramyxoviridae family. The disease, initially reported 
only in West Africa has now spread and is currently endemic in most of Africa (including the 
Maghreb), the Middle East, South Asia and China. Because of its high economic impact, PPR is 
considered one of the major livestock diseases. PPRV is mainly excreted through oculo-nasal 
discharge and spreads by contact between animals. Typical signs are fever, oculo-nasal 
discharge, diarrhea and dyspnea, associated with necrosis of the digestive and respiratory tracts. 
Morbidity and mortality rates reach up to 100% and 90% respectively. Goats are usually more 
susceptible than sheep.  
 
Material and Methods: Twenty PPRV naïve goats were randomly allocated to 2 groups, 
balanced on weights. One group served as controls whereas the other vaccinated with a single 
dose of PPR-VAC (BVI, Gaborone, Botswana*). Twenty one days later, the 20 goats were infected 
intranasally with a virulent PPRV strain (Morocco 2008). Monitoring of clinical signs, weight, viral 
excretion (real-time RT-PCR [1]) and serological response (competitive ELISA) were performed 
throughout the 14 days post challenge (dpc).  
 
Results: Control goats presented typical and severe clinical signs of PPR: fever, anorexia, nasal 
and ocular discharge, nasal mucosa lesions, diarrhea and weight loss. The intensity of clinical 
signs was maximal at 11 dpc. At that time, 4 control goats were euthanized on ethical ground. All 
control goats excreted high titres of PPRV genome after challenge. 
Conversely, very few and mild clinical signs were observed in the vaccinated goats and they did 
not lose weight. Moreover, the vaccine completely prevented viral excretion in all vaccinates. 
 
Conclusions: These results confirm the suitability of our challenge model for the clinical and 
virological assessment of PPRV infection.  
Further, these results demonstrate that vaccination with PPR-VAC® fully protects against clinical 
signs and weight loss (clinical protection), and completely prevents viral excretion 
(epidemiological control). 
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*: PPR-VAC is manufactured by the Botswana Vaccine Institute in cooperation with Merial.Merial 
is now a part of Boehringer Ingelheim. 
  
